Riki Ninomiya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Riki Ninomiya has a total of 451 co-authors. Here are the top co-authors by number of shared publications:
Masahiko Komagome
Department of Hepato-Biliary-Pancreatic Surgery and Pediatric Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
5 shared publicationsAkifumi Kimura
Department of Hepato-Biliary-Pancreatic Surgery and Pediatric Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
4 shared publicationsAkira Maki
Department of Hepatobiliary and Pancreatic Surgery, Saitama Medical Center Saitama Medical University Kawagoe‐shi Japan
4 shared publicationsYoshifumi Beck
Department of Hepato-Biliary-Pancreatic Surgery and Pediatric Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
4 shared publications- Yoshifumi Beck
Department of Hepato-Biliary-Pancreatic Surgery and Pediatric Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan
4 shared publications - Nobuyuki Takemura
Department of Hepato-Biliary-Pancreatic Surgery and Pediatric Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan
3 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Elsevier in Surgical Oncology
- Vol. 69
International survey on neoadjuvant treatments in anatomically resectable pancreatic adenocarcinoma (INSPIRA): a real-life snapshot
- 26 October 2026
- Published by Elsevier in Surgical Oncology
- Vol. 69
Open AccessInternational survey on neoadjuvant treatments in anatomically resectable pancreatic adenocarcinoma (INSPIRA): a real-life snapshot
- Open Access
- 14 October 2026
- Published by Springer Nature in Langenbeck's Archives of Surgery
Sensor-assisted firing execution (SAFE) cut: a quantitatively standardized technique for pancreatic transection in robotic distal pancreatectomy
Purpose: In robotic distal pancreatectomy (RDP), the lack of haptic feedback and delegation of stapler firing to the bedside assistant make compression quality during transection highly operator-dependent. We describe the “SAFE Cut” (Sensor-Assisted Firing Execution) technique, a quantitatively standardized protocol that converts the subjective “wait-and-fire” judgment into an objective, device-guided workflow. Methods: A smart stapler displays tissue resistance as nine stratifications across three color-coded Zones (1–1 to 3–3). A mandatory pre-firing wait (immediate to 60 s) was assigned to each segment and re-applied at every incremental firing step. We reviewed 31 consecutive patients undergoing RDP with the SAFE Cut technique, analyzing prospectively recorded Zone observations for all firing steps. Results: The protocol was completed without protocol-related conversion, repositioning, or technical failure in all 31 patients (31 of 31); in every case the stapler was operated by a bedside trainee. Median transection time was 13.3 min (8.7–23.0). CR-POPF occurred in 1 patient (3.2%), with no Grade C fistula and no 90-day mortality. Across 1,179 firing steps, Zone 1 occurred in 940 (79.7%) and Zone 2 in 239 (20.3%); Zone 3 never occurred. Because each step advances the stapler to new tissue, consecutive readings sample different segments; the step after a Zone 2 reading displayed Zone 1 in 136 of 239 events (56.9%). Conclusion: The SAFE Cut technique is feasible: the Zone-guided protocol was completed in every patient by a bedside trainee, making the previously hidden heterogeneity of tissue resistance quantifiable. This study was not designed to test fistula prevention; the CR-POPF rate was low, but a study of this size cannot establish efficacy, and whether the approach reduces fistula, and whether comparably low rates recur in other cohorts, needs prospective study.
- 14 October 2026
- Published by Springer Nature in Langenbeck's Archives of Surgery
Open AccessSensor-assisted firing execution (SAFE) cut: a quantitatively standardized technique for pancreatic transection in robotic distal pancreatectomy
Purpose: In robotic distal pancreatectomy (RDP), the lack of haptic feedback and delegation of stapler firing to the bedside assistant make compression quality during transection highly operator-dependent. We describe the “SAFE Cut” (Sensor-Assisted Firing Execution) technique, a quantitatively standardized protocol that converts the subjective “wait-and-fire” judgment into an objective, device-guided workflow. Methods: A smart stapler displays tissue resistance as nine stratifications across three color-coded Zones (1–1 to 3–3). A mandatory pre-firing wait (immediate to 60 s) was assigned to each segment and re-applied at every incremental firing step. We reviewed 31 consecutive patients undergoing RDP with the SAFE Cut technique, analyzing prospectively recorded Zone observations for all firing steps. Results: The protocol was completed without protocol-related conversion, repositioning, or technical failure in all 31 patients (31 of 31); in every case the stapler was operated by a bedside trainee. Median transection time was 13.3 min (8.7–23.0). CR-POPF occurred in 1 patient (3.2%), with no Grade C fistula and no 90-day mortality. Across 1,179 firing steps, Zone 1 occurred in 940 (79.7%) and Zone 2 in 239 (20.3%); Zone 3 never occurred. Because each step advances the stapler to new tissue, consecutive readings sample different segments; the step after a Zone 2 reading displayed Zone 1 in 136 of 239 events (56.9%). Conclusion: The SAFE Cut technique is feasible: the Zone-guided protocol was completed in every patient by a bedside trainee, making the previously hidden heterogeneity of tissue resistance quantifiable. This study was not designed to test fistula prevention; the CR-POPF rate was low, but a study of this size cannot establish efficacy, and whether the approach reduces fistula, and whether comparably low rates recur in other cohorts, needs prospective study.
- Open Access
- 21 January 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer
Objective: To identify prognostic factors, including preoperative treatment duration, among patients who underwent conversion surgery (CS) for unresectable locally advanced pancreatic cancer (UR-LAPC). Background: While CS has been increasingly adopted for UR-LAPC, optimal perioperative strategies remain controversial. Methods: This multicenter study included 465 UR-LAPC patients who underwent CS following preoperative chemotherapy with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP) from 2015 to 2020 at 84 Japanese institutions. Results: Median overall survival (OS) from treatment initiation was 43.8 months with a 5-year survival rate of 37.2%. A prognostic cutoff for preoperative treatment duration was identified at 6.1 months using maximally selected rank statistics. Patients receiving >6 months of preoperative treatment (n=350) demonstrated significantly better OS (50.4 vs. 29.7 mo) and recurrence-free survival (RFS) (15.6 vs. 9.1 mo) compared with those receiving ≤6 months (n=115, both P 6 months, FFX-based regimens, normal tumor markers (CA19-9 and CEA), and a prognostic nutritional index ≥45 before CS. These four preoperative factors enabled clear prognostic stratification: patients with ≥3 factors showed significantly improved survival compared with those with ≤2 factors (HR 0.44, P <0.0001; 5-year OS: 59.8% vs. 26.3%). Conclusions: The combination of four preoperative prognostic factors may enable risk stratification among patients undergoing CS for UR-LAPC. These findings may help inform treatment sequencing and patient selection, although external validation is needed to confirm their generalizability.
- 21 January 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Open AccessClinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer
Objective: To identify prognostic factors, including preoperative treatment duration, among patients who underwent conversion surgery (CS) for unresectable locally advanced pancreatic cancer (UR-LAPC). Background: While CS has been increasingly adopted for UR-LAPC, optimal perioperative strategies remain controversial. Methods: This multicenter study included 465 UR-LAPC patients who underwent CS following preoperative chemotherapy with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP) from 2015 to 2020 at 84 Japanese institutions. Results: Median overall survival (OS) from treatment initiation was 43.8 months with a 5-year survival rate of 37.2%. A prognostic cutoff for preoperative treatment duration was identified at 6.1 months using maximally selected rank statistics. Patients receiving >6 months of preoperative treatment (n=350) demonstrated significantly better OS (50.4 vs. 29.7 mo) and recurrence-free survival (RFS) (15.6 vs. 9.1 mo) compared with those receiving ≤6 months (n=115, both P 6 months, FFX-based regimens, normal tumor markers (CA19-9 and CEA), and a prognostic nutritional index ≥45 before CS. These four preoperative factors enabled clear prognostic stratification: patients with ≥3 factors showed significantly improved survival compared with those with ≤2 factors (HR 0.44, P <0.0001; 5-year OS: 59.8% vs. 26.3%). Conclusions: The combination of four preoperative prognostic factors may enable risk stratification among patients undergoing CS for UR-LAPC. These findings may help inform treatment sequencing and patient selection, although external validation is needed to confirm their generalizability.
- 27 September 2024
- Published by Wiley in Asian Journal of Endoscopic Surgery
- Vol. 17 (4) , e13388
A case of robotic distal pancreatectomy for solitary fibrous tumor of the pancreas
Solitary fibrous tumor (SFT) is a spindle cell tumor driven by the NAB2‐STAT6 fusion gene. While it can originate from any soft tissue, primary SFT of the pancreas is rare with limited reports. A 36‐year‐old man came to our department due to abdominal pain. Computed tomography revealed a circular mass with weak peripheral enhancement and an internal cyst in the pancreatic tail. Diagnosis was not confirmed through endoscopic ultrasound‐guided biopsy, and differential diagnoses included acinar cell carcinoma and pancreatic neuroendocrine tumor. A robotic distal pancreatectomy with splenectomy was performed, and the patient was discharged 11 days postoperatively. Histopathological examination showed an irregular arrangement of spindle cells, and immunohistochemical staining was positive for CD34 and STAT6, confirming an SFT diagnosis with low metastatic risk. Robotic surgery effectively managed this tumor.
- 27 September 2024
- Published by Wiley in Asian Journal of Endoscopic Surgery
- Vol. 17 (4) , e13388
A case of robotic distal pancreatectomy for solitary fibrous tumor of the pancreas
Solitary fibrous tumor (SFT) is a spindle cell tumor driven by the NAB2‐STAT6 fusion gene. While it can originate from any soft tissue, primary SFT of the pancreas is rare with limited reports. A 36‐year‐old man came to our department due to abdominal pain. Computed tomography revealed a circular mass with weak peripheral enhancement and an internal cyst in the pancreatic tail. Diagnosis was not confirmed through endoscopic ultrasound‐guided biopsy, and differential diagnoses included acinar cell carcinoma and pancreatic neuroendocrine tumor. A robotic distal pancreatectomy with splenectomy was performed, and the patient was discharged 11 days postoperatively. Histopathological examination showed an irregular arrangement of spindle cells, and immunohistochemical staining was positive for CD34 and STAT6, confirming an SFT diagnosis with low metastatic risk. Robotic surgery effectively managed this tumor.
- Open Access
- 24 July 2024
- Published by Springer Nature in Surgical Endoscopy
- Vol. 38 (9) , 5422-5429
Reduced-port robotic pancreaticoduodenectomy with optimized surgical field deployment: early results of single-site plus-two ports method
Background: The adoption of Robotic Pancreaticoduodenectomy (RPD) is increasing globally. Meanwhile, reduced-port RPD (RPRPD) remains uncommon, requiring robot-specific techniques not possible with laparoscopy. We introduce a unique RPRPD technique optimizing surgical field exposure. Methods: Our RPRPD utilizes a single-site plus-two ports technique, facilitated by a single-port platform through a 5-cm incision. The configuration of robotic arms (arm1, arm2, arm3, and arm4) were strategically designed for optimal procedural efficiency, with the arms2 and arm3, alongside the assistant trocar, mounted on the single-port platform, while the arms1 and arm4 were positioned laterally across the abdomen. Drainage was established via channels created at the arm1 and arm4 insertion sites. A “gooseneck traction” was principally employed with the robotic instrument to prop up the specimen rather than grasp, improving the surgical field’s visibility and access. Clinical outcomes of patients who underwent RPRPD performed between August 2020 and September 2023 by a single surgeon across two centers in Taiwan and Japan were reviewed. Results: Fifty patients underwent RPRPD using the single-site plus-two ports technique. The gooseneck traction technique enabled goodsurgical field deployment and allowed for unrestricted movement of robotic arms with no collisions with the assistant instruments. The median operative time was 351 min (250–488 min), including 271 min (219–422 min) of console time and three minutes (2–10 min) of docking time. The median estimated blood loss was 80 mL (1–872 mL). All RPRPD procedures were successfully performed without the need for conversion to open surgery. Postoperative major morbidity (i.e., Clavien-Dindo grade ≥ IIIa) was observed in 6 (12%) patients and median postoperative hospital stay was 13 days. Conclusions: The single-site plus-two ports RPRPD with the gooseneck traction proves to be a safe, feasible option, facilitating surgical field visibility and robotic arm maneuverability. Graphical
- 24 July 2024
- Published by Springer Nature in Surgical Endoscopy
- Vol. 38 (9) , 5422-5429
Open AccessReduced-port robotic pancreaticoduodenectomy with optimized surgical field deployment: early results of single-site plus-two ports method
Background: The adoption of Robotic Pancreaticoduodenectomy (RPD) is increasing globally. Meanwhile, reduced-port RPD (RPRPD) remains uncommon, requiring robot-specific techniques not possible with laparoscopy. We introduce a unique RPRPD technique optimizing surgical field exposure. Methods: Our RPRPD utilizes a single-site plus-two ports technique, facilitated by a single-port platform through a 5-cm incision. The configuration of robotic arms (arm1, arm2, arm3, and arm4) were strategically designed for optimal procedural efficiency, with the arms2 and arm3, alongside the assistant trocar, mounted on the single-port platform, while the arms1 and arm4 were positioned laterally across the abdomen. Drainage was established via channels created at the arm1 and arm4 insertion sites. A “gooseneck traction” was principally employed with the robotic instrument to prop up the specimen rather than grasp, improving the surgical field’s visibility and access. Clinical outcomes of patients who underwent RPRPD performed between August 2020 and September 2023 by a single surgeon across two centers in Taiwan and Japan were reviewed. Results: Fifty patients underwent RPRPD using the single-site plus-two ports technique. The gooseneck traction technique enabled goodsurgical field deployment and allowed for unrestricted movement of robotic arms with no collisions with the assistant instruments. The median operative time was 351 min (250–488 min), including 271 min (219–422 min) of console time and three minutes (2–10 min) of docking time. The median estimated blood loss was 80 mL (1–872 mL). All RPRPD procedures were successfully performed without the need for conversion to open surgery. Postoperative major morbidity (i.e., Clavien-Dindo grade ≥ IIIa) was observed in 6 (12%) patients and median postoperative hospital stay was 13 days. Conclusions: The single-site plus-two ports RPRPD with the gooseneck traction proves to be a safe, feasible option, facilitating surgical field visibility and robotic arm maneuverability. Graphical
- 18 March 2024
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 28 (6) , 945-947
Innovative staple line reinforcement and suturing technique: impact on postoperative pancreatic fistula rates in distal pancreatectomy
- 18 March 2024
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 28 (6) , 945-947
Innovative staple line reinforcement and suturing technique: impact on postoperative pancreatic fistula rates in distal pancreatectomy
- 24 September 2023
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 30 (11) , E73-E74
Right lateral approach to the superior mesenteric artery in robotic pancreaticoduodenectomy
- 24 September 2023
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 30 (11) , E73-E74
Right lateral approach to the superior mesenteric artery in robotic pancreaticoduodenectomy
- Open Access
- 20 April 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46 (9) , 3542-3548
Predicting conversion surgery in patients with locally advanced pancreatic cancer after modified FOLFIRINOX treatment
- 20 April 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46 (9) , 3542-3548
Open AccessPredicting conversion surgery in patients with locally advanced pancreatic cancer after modified FOLFIRINOX treatment
- Open Access
- 1 March 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (5) , 925
The Efficacy of S-1 as Adjuvant Chemotherapy for Resected Biliary Tract Carcinoma: A Propensity Score-Matching Analysis
Even though S-1 is a widely used chemotherapeutic agent, there is no evidence for its use in an adjuvant setting for biliary tract carcinoma (BTC). Patients who underwent surgical treatment for BTC between August 2007 and December 2018 were selected. Propensity score matching was performed between patients who received S-1 as adjuvant chemotherapy (S-1 group) and those who underwent surgical treatment alone (observation group). Of 170 eligible patients, 38 patients were selected in each group after propensity score matching. Among those in the matched cohort, both the median recurrence-free survival (RFS) and overall survival (OS) in the S-1 group were significantly longer than those in the observation group (RFS, 61.2 vs. 13.1 months, p = 0.033; OS, not available vs. 28.2 months, p = 0.003). A multivariate analysis of the OS revealed that perineural invasion and adjuvant S-1 chemotherapy were independent prognostic factors. According to a subgroup analysis of the OS, the S-1 group showed significantly better prognoses than the observation group among patients with perineural invasion (p < 0.001). S-1 adjuvant chemotherapy might improve the prognosis of BTC, especially in patients with perineural invasion.
- 1 March 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (5) , 925
Open AccessThe Efficacy of S-1 as Adjuvant Chemotherapy for Resected Biliary Tract Carcinoma: A Propensity Score-Matching Analysis
Even though S-1 is a widely used chemotherapeutic agent, there is no evidence for its use in an adjuvant setting for biliary tract carcinoma (BTC). Patients who underwent surgical treatment for BTC between August 2007 and December 2018 were selected. Propensity score matching was performed between patients who received S-1 as adjuvant chemotherapy (S-1 group) and those who underwent surgical treatment alone (observation group). Of 170 eligible patients, 38 patients were selected in each group after propensity score matching. Among those in the matched cohort, both the median recurrence-free survival (RFS) and overall survival (OS) in the S-1 group were significantly longer than those in the observation group (RFS, 61.2 vs. 13.1 months, p = 0.033; OS, not available vs. 28.2 months, p = 0.003). A multivariate analysis of the OS revealed that perineural invasion and adjuvant S-1 chemotherapy were independent prognostic factors. According to a subgroup analysis of the OS, the S-1 group showed significantly better prognoses than the observation group among patients with perineural invasion (p < 0.001). S-1 adjuvant chemotherapy might improve the prognosis of BTC, especially in patients with perineural invasion.
- Open Access
- 1 January 2019
- Published by Japan Surgical Association in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
- Vol. 80 (5) , 957-963
A Case of Hepatic Rupture Associated with a Right-sided Round Ligament Related to Partial Hellp Syndrome
37歳,女性.双胎妊娠24週0日に妊娠高血圧症候群の増悪のため緊急帝王切開術を施行した.術後出血および肝逸脱酵素上昇を契機として,CTでpartial HELLP(hemolysis, elevated liver enzymes, low platelet count)症候群に続発した右肝柀膜下血腫からの肝破裂と診断し,同時に右側肝円索を有することが判明した.出血が持続したため経カテーテル的動脈塞栓術(transcatheter arterial embolization:TAE)で止血した.TAEから10日後に,肝梗塞に陥った肝右外側領域と右傍正中領域背側部を切除した.重篤な周産期合併症として発症した肝破裂であり,かつ肝に稀な解剖学的変異も有していた症例に対し,緊急のTAEと待機的な肝切除を,段階的に組み合わせて救命できたため報告する.
- 1 January 2019
- Published by Japan Surgical Association in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
- Vol. 80 (5) , 957-963
Open AccessA Case of Hepatic Rupture Associated with a Right-sided Round Ligament Related to Partial Hellp Syndrome
37歳,女性.双胎妊娠24週0日に妊娠高血圧症候群の増悪のため緊急帝王切開術を施行した.術後出血および肝逸脱酵素上昇を契機として,CTでpartial HELLP(hemolysis, elevated liver enzymes, low platelet count)症候群に続発した右肝柀膜下血腫からの肝破裂と診断し,同時に右側肝円索を有することが判明した.出血が持続したため経カテーテル的動脈塞栓術(transcatheter arterial embolization:TAE)で止血した.TAEから10日後に,肝梗塞に陥った肝右外側領域と右傍正中領域背側部を切除した.重篤な周産期合併症として発症した肝破裂であり,かつ肝に稀な解剖学的変異も有していた症例に対し,緊急のTAEと待機的な肝切除を,段階的に組み合わせて救命できたため報告する.